A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer

NCT07489716 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: SHR-1826

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.